That such TP53 genetic alterations occur at high frequency in many cancer types implies that they have very strong selective advantages for the expanding cancer cell clones [1, 2]; indeed this is borne out in experimental data on cell lines and animal models of cancer [3, 4]. The gene discussed is TP53; the disease is cancer.